MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-29-2024
Atrion Corporation Income Statement 2011-2026 | ATRI
Annual Income Statement Atrion Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
639 M | 1.22 B | 1.3 B | 1.14 B | 1.3 B | 1.42 B | 1.05 B | 905 M | 693 M | 656 M | 547 M | 404 M | 491 M |
Shares |
1.76 M | 1.79 M | 1.81 M | 1.84 M | 1.86 M | 1.85 M | 1.85 M | 1.82 M | 1.85 M | 1.96 M | 2.01 M | 2.02 M | 2.02 M |
Historical Prices |
363 | 683 | 715 | 622 | 607 | 768 | 571 | 469 | 358 | 307 | 271 | 182 | 180 |
Net Income |
19.4 M | 35 M | 33.1 M | 32.1 M | 36.8 M | 34.3 M | 36.6 M | 27.6 M | 28.9 M | 27.8 M | 26.6 M | 23.6 M | 26 M |
Revenue |
169 M | 184 M | 165 M | 148 M | 155 M | 152 M | 147 M | 143 M | 146 M | 141 M | 132 M | 119 M | 118 M |
Cost of Revenue |
107 K | 108 K | 95.6 K | 81.4 M | 84.4 M | 80.7 M | 75.8 M | 75.9 M | - | - | - | - | - |
Gross Profit |
62.4 K | 75.9 K | 69.4 K | 66.2 M | 70.7 M | 71.8 M | 70.8 M | 67.6 M | 71 M | 68.5 M | 63.1 M | 56.1 M | 60 M |
Operating Income |
22.6 K | 39.7 K | 36 K | 35.7 M | 40.5 M | 41.7 M | 41.3 M | 39.1 M | 42.5 M | 40.8 M | 37.9 M | 33.6 M | 38.2 M |
Interest Expense |
149 | - | - | - | - | 42 K | 1 K | -308 K | -2.41 M | 13 K | 8 K | 2 K | 12 K |
EBITDA |
37.7 K | 53.5 K | 48.9 K | 47.3 M | 51.4 M | 50.8 M | 50 M | 48.1 M | 51.3 M | 49.5 M | 46.5 M | 41.2 M | 44.7 M |
Operating Expenses |
39.8 K | 36.2 K | 33.3 K | 30.5 M | 30.2 M | 30.1 M | 29.5 M | 28.5 M | 28.5 M | 27.7 M | 25.1 M | 22.5 M | 21.8 M |
General and Administrative Expenses |
23.2 K | 20.9 K | 19.6 K | 17.3 M | 16.3 M | 16.2 M | 16.4 M | 15.3 M | 16.1 M | 16.2 M | 14.6 M | 13.1 M | 13.6 M |
All numbers in USD currency
Quarterly Income Statement Atrion Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.76 M | 1.76 M | 1.76 M | - | 1.79 M | 1.79 M | 1.8 M | - | 1.8 M | 1.83 M | 1.83 M | - | 1.83 M | 1.84 M | 1.85 M | - | 1.86 M | 1.85 K | 1.85 K | - | 1.85 K | 1.85 K | 1.85 K | - | 1.85 K | 1.84 K | 1.84 K | - | 1.82 K | 1.82 K | 1.82 K | - | 1.84 K | 1.85 K | 1.88 K | - | 1.95 K | 1.96 K | 1.98 K | - | 2.01 K | 2.02 K | 2.02 M | - | 2.01 M | 2.02 M | 2.02 M | - | 2.02 M | 2.02 M | 2.02 M |
Net Income |
2.94 M | 6.56 M | 3.48 M | - | 8.84 M | 9.35 M | 8.5 M | - | 8.28 M | 8.92 M | 7.73 M | - | 7.24 M | 8.6 M | 8.9 M | 8.06 M | 9.6 M | 9.66 M | 9.44 M | 7.75 M | 9.22 M | 8.8 M | 8.49 M | 8.65 M | 7.97 M | 10 M | 9.95 M | 5.57 M | 7.61 M | 7.45 M | 6.94 M | 6.05 M | 7.8 M | 15.1 M | 7.6 M | 6.04 M | 7.68 M | 6.88 M | 7.2 M | 5.77 M | 7.67 M | 6.51 M | 6.64 M | 4.89 M | 7.26 M | 6.1 M | 5.38 M | 5.39 M | 6.77 M | 7.02 M | 6.86 M |
Revenue |
41.9 M | 43.8 M | 40 M | - | 44.6 M | 48.9 M | 47.1 M | - | 42.9 M | 42.7 M | 39.2 M | - | 33.8 M | 38 M | 43.6 M | 34.5 M | 38.9 M | 40.1 M | 41.6 M | 34.9 M | 39.3 M | 38.8 M | 39.4 M | 34 M | 37.9 M | 36.2 M | 38.5 M | 33.3 M | 37.8 M | 36.1 M | 36.2 M | 32.4 M | 37.4 M | 37.7 M | 38.3 M | 32.7 M | 36.6 M | 35 M | 36.4 M | 31.9 M | 34 M | 32.6 M | 33.5 M | 28.5 M | 30.6 M | 30.7 M | 29.2 M | 25.5 M | 30.5 M | 31.1 M | 30.6 M |
Cost of Revenue |
28.2 M | 26.6 M | 24.9 M | - | 27 M | 28 M | 27.9 M | - | 42.9 M | 24.8 M | 22.8 M | - | 33.8 M | 38 M | 23.7 M | - | 38.9 M | 40.1 M | 22.9 M | - | 21.3 M | 19.6 M | 20.4 M | - | 19.5 M | 18.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
13.7 M | 17.3 M | 15.1 M | - | 17.7 M | 20.8 M | 19.2 M | - | 17.8 M | 17.9 M | 16.3 M | - | 14.9 M | 17.5 M | 19.9 M | - | 17.9 M | 18.6 M | 18.7 M | - | 18 M | 19.2 M | 19 M | - | 18.4 M | 17.7 M | 18.6 M | - | 17.6 M | 17.2 M | 17.6 M | - | 18.4 M | 18.8 M | 18.5 M | - | 18 M | 17.4 M | 17.4 M | - | 17 M | 15.6 M | 15.7 M | - | 14.9 M | 14.7 M | 13.8 M | - | 15.3 M | 16.5 M | 15.6 M |
Operating Income |
4.07 M | 7.38 M | 4.47 M | - | 9.6 M | 11 M | 10.2 M | - | 9.48 M | 9.8 M | 8.93 M | - | 7.58 M | 10 M | 11.7 M | 8.08 M | 10.4 M | 11 M | 11 M | 10.8 M | 10.8 M | 11.3 M | 11.4 M | 8.29 M | 11.5 M | 10.2 M | 11.3 M | 7.61 M | 11 M | 10.1 M | 10.5 M | 8.33 M | 11.6 M | 11.1 M | 11.5 M | 8.63 M | 11.2 M | 10.3 M | 10.7 M | 8.34 M | 10.7 M | 9.5 M | 9.4 M | 7.04 M | 9.68 M | 8.97 M | 7.94 M | 7.63 M | 10 M | 10.4 M | 10.1 M |
Interest Expense |
97 K | 27 K | - | - | - | - | - | - | - | - | - | - | - | - | -535 K | - | -106 K | 354 K | 793 K | - | 21 K | -408 K | -772 K | - | - | - | 1 K | - | 1 K | 36 K | -345 K | - | - | - | - | - | 12 K | - | 1 K | - | - | - | - | - | 2 K | 2 K | 2 K | - | - | - | - |
EBITDA |
- | 7.41 M | 7.98 M | - | 19.9 M | 11.1 M | 13.7 M | - | 19 M | 16 M | 12 M | - | 16.1 M | 15.6 M | 14.5 M | 8.08 M | 18.4 M | 16.2 M | 13.6 M | 10.8 M | 17.5 M | 15.7 M | 13.5 M | 8.29 M | 17.9 M | 14.4 M | 13.4 M | 7.61 M | 17.6 M | 14.5 M | 12.7 M | 8.33 M | 18.2 M | 15.6 M | 13.7 M | 8.63 M | 17.9 M | 14.7 M | 13 M | 8.34 M | 17.1 M | 13.8 M | 11.5 M | 7.04 M | 15.2 M | 12.5 M | 9.66 M | 7.63 M | 14.9 M | 13.6 M | 11.7 M |
Operating Expenses |
9.67 M | 9.88 M | 10.6 M | - | 8.05 M | 9.8 M | 8.99 M | - | 8.31 M | 8.07 M | 7.41 M | - | 7.32 M | 7.42 M | 8.15 M | - | 7.44 M | 7.63 M | 7.67 M | - | 7.24 M | 7.96 M | 7.58 M | - | 6.93 M | 7.52 M | 7.3 M | - | 6.65 M | 7.14 M | 7.1 M | - | 6.81 M | 7.66 M | 7.04 M | - | 6.81 M | 7.15 M | 6.69 M | - | 6.33 M | 6.14 M | 6.31 M | - | 5.22 M | 5.71 M | 5.89 M | - | 5.29 M | 6.02 M | 5.46 M |
General and Administrative Expenses |
5.45 M | 5.95 M | 6.25 M | - | 4.49 M | 5.62 M | 5.1 M | - | 4.84 M | 4.75 M | 4.17 M | - | 4.04 M | 4.63 M | 4.4 M | - | 3.99 M | 4.3 M | 4.19 M | - | 3.93 M | 4.31 M | 4.23 M | - | 4.09 M | 4.29 M | 4.02 M | - | 3.61 M | 3.88 M | 3.95 M | - | 3.93 M | 4.31 M | 3.96 M | - | 4.15 M | 4.39 M | 3.93 M | - | 3.65 M | 3.71 M | 3.59 M | - | 3.16 M | 3.4 M | 3.47 M | - | 3.29 M | 3.95 M | 3.38 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Atrion Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
$ 70.29 | 0.17 % | $ 14 B |  USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 74.63 | 0.09 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Baxter International
BAX
|
$ 16.65 | -0.18 % | $ 8.54 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.27 | -1.23 % | $ 888 M | USA |
 |
AtriCure
ATRC
|
$ 29.19 | 0.41 % | $ 1.39 B | USA |
 |
electroCore
ECOR
|
$ 7.04 | 3.53 % | $ 59.7 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 9.75 | 3.72 % | $ 23.7 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 116.69 | 3.48 % | $ 5.65 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 58.46 | 2.87 % | $ 2.94 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 5.53 | 6.35 % | $ 245 M | USA |
 |
ICU Medical
ICUI
|
$ 122.99 | -0.26 % | $ 3.03 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.43 | 1.51 % | $ 195 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 117.22 | 0.36 % | $ 3.75 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 452.58 | 0.11 % | $ 162 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.26 | -1.39 % | $ 197 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 109.16 | 0.62 % | $ 2.47 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.49 | -0.06 % | $ 9.51 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.36 | -1.67 % | $ 108 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 1.9 % | $ 23.8 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 67.81 | 0.16 % | $ 4.01 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.81 | - | $ 4.34 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Pro-Dex
PDEX
|
$ 48.53 | -6.08 % | $ 160 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 22.94 | -0.26 % | $ 1.55 B | USA |
 |
ResMed
RMD
|
$ 224.93 | 0.37 % | $ 32.9 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.71 | 2.98 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 20.96 | 3.71 % | $ 1.04 B | USA |
 |
STERIS plc
STE
|
$ 219.97 | 0.58 % | $ 21.7 B | USA |
 |
Stereotaxis
STXS
|
$ 1.88 | -0.53 % | $ 171 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 115.04 | -2.35 % | $ 5.13 B | USA |
 |
Utah Medical Products
UTMD
|
$ 62.93 | -0.3 % | $ 204 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 256.85 | 0.8 % | $ 18.6 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.64 | 0.09 % | $ 2.32 B | USA |
 |
AngioDynamics
ANGO
|
$ 9.84 | -4.56 % | $ 402 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 155.32 | 0.52 % | $ 44.7 B | USA |
 |
Nephros
NEPH
|
$ 2.86 | -0.35 % | $ 29.7 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.08 | - | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
$ 116.95 | -0.7 % | $ 6.52 M | USA |